Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia

Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic leukemia (ALL). Prior studies on the genetics of osteonecrosis have focused on patients ≥10 years of age, leaving the genetic risk factors for the larger group of children

Saved in:
Bibliographic Details
Published in:Blood 2016-02, Vol.127 (5), p.558-564
Main Authors: Karol, Seth E., Mattano, Leonard A., Yang, Wenjian, Maloney, Kelly W., Smith, Colton, Liu, ChengCheng, Ramsey, Laura B., Fernandez, Christian A., Chang, Tamara Y., Neale, Geoffrey, Cheng, Cheng, Mardis, Elaine, Fulton, Robert, Scheet, Paul, San Lucas, F. Anthony, Larsen, Eric C., Loh, Mignon L., Raetz, Elizabeth A., Hunger, Stephen P., Devidas, Meenakshi, Relling, Mary V.
Format: Article
Language:English
Subjects:
Bone Morphogenetic Protein 7 - genetics
Child
Child, Preschool
Clinical Trials and Observations
Female
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Infant
Male
Osteonecrosis - epidemiology
Osteonecrosis - genetics
Polymorphism, Single Nucleotide
Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic leukemia (ALL). Prior studies on the genetics of osteonecrosis have focused on patients ≥10 years of age, leaving the genetic risk factors for the larger group of children
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2015-10-673848